1037 GMT - Fevertree's partnership with Molson Coors in the U.S. represents a meaningful change in the U.K. mixer-maker's investment case, Goodbody analyst Fintan Ryan says in a note. On the positive side, Fevertree will receive cash up front to return to shareholders while Molson Coors will assume the operational costs and risks from executing the long-term growth potential of the brand in the U.S., the analyst says. However, Fevertree will also lose direct control of its largest market, a region where the company still is performing well and has the clearest strategy for market share growth, the analyst adds. Shares are up almost 25% at 814.0 pence, on track for their biggest intraday rise. (michael.susin@wsj.com)
(END) Dow Jones Newswires
January 30, 2025 05:39 ET (10:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。